Drug intelligence / Profile preview

YSKB-1001

Development stage: Unknown
Administration: Intravenous

Overview

YSKB-1001 is an investigational drug that has been evaluated in a Phase I clinical trial for patients with advanced solid tumors. Specific details regarding its mechanism of action, molecular target, modality, or chemical structure are not publicly available as of June 2025. The drug appears to be under early-stage clinical development and is being studied for its safety and potential efficacy in oncology settings[1].

Beyond the preview

Go deeper on YSKB-1001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YSKB-1001.

Explore the full profile